Lilia Böckels

Dr. Lilia Böckels


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
LBLilia Böckels
Lilia Böckels
DADaniel Alexa
Daniel Alexa
DADorin Cristian Antal
Dorin Cristian Antal
CGCristina Gatcan
Cristina Gatcan
CACosmin Alecu
Cosmin Alecu
Dan Iulian CuciureanuDan Iulian Cuciureanu
Dan Iulian Cuciureanu
The gut microbiota has emerged as a central regulator of the gut–brain axis, profoundly influencing neural, immune, and metabolic homeostasis. Increasing evidence indicates that disturbances in microbial composition and function contribute to the onset and progression of neurodegenerative diseases (NDs) through mechanisms involving neuroinflammation, oxidative stress, and impaired neurotransmission. Gut dysbiosis is characterized by a loss of microbial diversity, a reduction in beneficial commensals, and an enrichment of pro-inflammatory taxa. These shifts alter intestinal permeability and systemic immune tone, allowing microbial metabolites and immune mediators to affect central nervous system (CNS) integrity. Metabolites such as short-chain fatty acids (SCFAs), tryptophan derivatives, lipopolysaccharides (LPS), and trimethylamine N-oxide (TMAO) modulate blood–brain barrier (BBB) function, microglial activation, and neurotransmitter synthesis, linking intestinal imbalance to neuronal dysfunction and cognitive decline. Disruption of this gut–brain communication network promotes chronic inflammation and metabolic dysregulation, key features of neurodegenerative pathology. SCFA-producing and tryptophan-metabolizing bacteria appear to exert neuroprotective effects by modulating immune responses, epigenetic regulation, and neuronal resilience. The aim of this work was to comprehensively explore the current evidence on the bidirectional communication between the gut microbiota and the CNS, with a focus on identifying the principal molecular, immune, and metabolic mechanisms supported by the strongest and most consistent data. By integrating findings from recent human studies, this review sought to clarify how microbial composition and function influence neurochemical balance, immune activation, and BBB integrity, ultimately contributing to the onset and progression of neurodegenerative processes. Collectively, these findings position the gut microbiota as a dynamic interface between the enteric and CNS, capable of influencing neurodegenerative processes through immune and metabolic signaling.

14 November 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Ciubotaru Alin FlorentinCiubotaru Alin Florentin
Ciubotaru Alin Florentin
DADaniel Alexa
Daniel Alexa
CGCristina Grosu
Cristina Grosu
LBLilia Böckels
Lilia Böckels
IPIoana Pavaleanu
Ioana Pavaleanu
EIEmilian Bogdan Ignat
Emilian Bogdan Ignat
Background/Objectives: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by progressive impairment of neuronal transmission due to focal demyelination. The most common form is RRMS (relapsing-remitting multiple sclerosis), which, under the influence of certain factors, can progress to SPMS (secondary progressive multiple sclerosis). Our study aimed to validate the criteria proposed by a working group of the Romanian Society of Neurology versus the criteria proposed by a group of experts from Spain, Karolinska, and Croatia concerning the progression from RRMS to SPMS. Methods: This was done by gathering epidemiological data (age, gender) and by applying clinical tests such as the 9HPT (9-hole peg test), 25FWT (25-foot walk test), and EDSS (expanded disability status scale) tests and the SDMT test (symbol digit modalities test). The present research is a cohort study that included a number of 120 patients diagnosed with MS according to the McDonald Diagnostic Criteria 2017. The study was carried out between January 2023 and April 2024, including patients hospitalized in the Neurology Clinic of the Clinical Rehabilitation Hospital from Iasi, Romania. The data were collected at baseline (T0) and at a 12-month interval (T1). Results: The statistical analysis was conducted using Kaiser–Meyer–Olkin analysis, which indicated a value of 0.683, thus validating the clinical tests used. The correlation matrix and the linear regression for all the tests showed highly significant statistical results. Furthermore, the ROC curve analysis of the criteria suggested by the working group of the Romanian Society of Neurology demonstrated that the EDSS, 9HPT, and 25FWT are highly sensitive in diagnosing SPMS, an opinion that is shared with the Spanish experts, but not with the Karolinska expert panel. Using the criteria given by the Croatian expert group in the ROC curve analysis showed that only the EDSS was strongly significant for the progression to the SPMS phase. Conclusions: In conclusion, all clinical methods used demonstrated that they are valid and can contribute to identifying patients with an increased risk of progression. The model proposed by the Romanian Society of Neurology working group is similar to other countries’ expert opinions and can be used to detect the risk of disease progression and establish a more tailored therapeutic management of SPMS.

Verified
Journal Article
Open access
PDF file
LBLilia Böckels
Lilia Böckels
VLVitalie Lisnic
Vitalie Lisnic
DADaniel Alexa
Daniel Alexa
ABAnna Belenciuc
Anna Belenciuc
RCRAUL ANDREI CRETU
RAUL ANDREI CRETU
Dan Iulian CuciureanuDan Iulian Cuciureanu
Dan Iulian Cuciureanu
Background/Objectives: Relapsing-remitting multiple sclerosis (RRMS) is frequently associated with anxiety and depressive symptoms, which significantly impact quality of life and clinical outcomes. The Hospital Anxiety and Depression Scale (HADS) is widely used to screen for psychological distress in medical populations. To perform a preliminary psychometric evaluation of the Romanian version of HADS in patients with RRMS, focusing on internal consistency and construct-related associations. Methods: This cross-sectional study included 60 RRMS patients. Internal consistency was assessed using Cronbach’s alpha and corrected item–total correlations. Construct-related evidence was explored through correlations with Expanded Disability Status Scale (EDSS) scores and disease duration, as well as known-groups comparisons based on disability level. Results: HADS demonstrated acceptable internal consistency (HADS-A α = 0.834; HADS-D α = 0.767). Depressive symptoms showed a moderate association with neurological disability (ρ = 0.456, p < 0.001), whereas no significant association was observed between anxiety symptoms and EDSS. Patients with higher disability had significantly higher HADS-D scores (p = 0.001), while HADS-A scores did not differ between groups. Conclusions: The Romanian version of HADS provides preliminary evidence of acceptable internal consistency and construct-related validity in RRMS. These findings support its potential use as a screening tool for psychological distress while highlighting the need for larger studies including factor analysis and test–retest reliability.